Shanghai Shyndec Pharmaceutical (600420) Fundamentals 2026 — P/E 16.6x, Revenue Analysis | SniperIQ
Shanghai Shyndec Pharmaceutical (600420) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥11.7B, trading at ¥8.76 on the SHH. This SniperIQ fundamentals page covers Shanghai Shyndec Pharmaceutical's valuation (P/E 16.6x, P/B 0.8x), profitability (net margin 8.1%), revenue (¥9.4B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Shanghai Shyndec Pharmaceutical's market cap?
Shanghai Shyndec Pharmaceutical (600420) has a market capitalization of approximately ¥11.7B, trading at ¥8.76 on the SHH. Market cap moves with the live share price.
What is Shanghai Shyndec Pharmaceutical's P/E ratio?
Shanghai Shyndec Pharmaceutical's trailing twelve-month P/E ratio is 16.6x, with a price-to-book (P/B) of 0.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Shanghai Shyndec Pharmaceutical?
Shanghai Shyndec Pharmaceutical runs a net profit margin of 8.1%, a gross margin of 30.1%, and an operating margin of 10.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Shanghai Shyndec Pharmaceutical generate?
Shanghai Shyndec Pharmaceutical reported revenue of ¥9.4B for fiscal year 2025, with net income of ¥944M and earnings per share (EPS) of 0.7. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Shanghai Shyndec Pharmaceutical pay a dividend?
Shanghai Shyndec Pharmaceutical offers a trailing dividend yield of about 3.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Shanghai Shyndec Pharmaceutical financially healthy?
Shanghai Shyndec Pharmaceutical carries a debt-to-equity ratio of 0.09x and a current ratio of 3.59x, with a market beta of 0.14. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Shanghai Shyndec Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Shanghai Shyndec Pharmaceutical (600420) the key facts are: market cap ¥11.7B, P/E 16.6x, revenue ¥9.4B, 52-week range 7.67-11.8. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Shanghai Shyndec Pharmaceutical's full fundamentals live
Get Shanghai Shyndec Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.